Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sihuan Pharmaceutical Holdings GroupSHPHF 60 5-Year Yield-on-Cost % is 2.22 as of Jul. 24, 2026, which is 17% above its 10-year median of 1.90. GuruFocus rates SHPHF with a GF Score™ of 60/100 and a GF Value™ of $0.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 513 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks worse than 50.1% on this metric.
SHPHF's 5-Year Yield-on-Cost % is ranked worse than 50.1% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs SHPHF: 2.22
Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sihuan Pharmaceutical Holdings Group 5-Year Yield-on-Cost % Related Terms
SHPHF vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's 5-Year Yield-on-Cost % falls into.
Sihuan Pharmaceutical Holdings Group 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Sihuan Pharmaceutical Holdings Group (SHPHF) has a 5-Year Yield-on-Cost % of 2.22 as of Jul. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. This is 17% above median its historical median of 1.90. Over the past decade, Sihuan Pharmaceutical Holdings Group's 5-Year Yield-on-Cost % has ranged from 0.42 to 6.89. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #257 out of 513 companies in the Drug Manufacturers industry, placing it in the top 50.1%.
Is Sihuan Pharmaceutical Holdings Group's 5-Year Yield-on-Cost % too high?
Sihuan Pharmaceutical Holdings Group's current 5-Year Yield-on-Cost % of 2.22 is 17% above median its 10-year median of 1.90. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 6.89. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.36. Sihuan Pharmaceutical Holdings Group's value of 2.22 is 5.9% below this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #257 out of 513 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #257 out of 513 companies for 5-Year Yield-on-Cost %. This places Sihuan Pharmaceutical Holdings Group in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. Sihuan Pharmaceutical Holdings Group's value of 2.22 is 5.9% below this benchmark. Historically, Sihuan Pharmaceutical Holdings Group's own 5-Year Yield-on-Cost % has ranged from 0.42 to 6.89 over the past decade. While the company's 10-year median is 1.90 vs. the industry median of 2.36, Sihuan Pharmaceutical Holdings Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current 5-Year Yield-on-Cost % of 2.22 is 5.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current 5-Year Yield-on-Cost % is 2.22, which is 17% above median its own 10-year median of 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.16, compared to a current price of $0.12 — trading 25% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.22, which is 17% above median its 10-year median of 1.90 and 5.9% below the Drug Manufacturers industry median of 2.36. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current 5-Year Yield-on-Cost % is 2.22 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $0.12 is trading 25% below its estimated GF Value™ of $0.16.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHF:
5-Year Yield-on-Cost %: 2.22 (17% above median its 10-year median of 1.90)
GF Value™: $0.16 vs. price of $0.12 (25% below fair value)
Industry Position: 5.9% below the Drug Manufacturers median (#257 of 513)
No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
60GF Score
Get the complete analysis for SHPHF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHF has been successfully added to your 
